Oncology Institute (NASDAQ:TOI) Earns “Buy” Rating from BTIG Research

Oncology Institute (NASDAQ:TOI)‘s stock had its “buy” rating reaffirmed by stock analysts at BTIG Research in a research note issued on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the stock. BTIG Research’s price target would suggest a potential upside of 59.45% from the stock’s current price.

TOI has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research report on Wednesday, October 8th. B. Riley began coverage on Oncology Institute in a research report on Wednesday, July 16th. They set a “buy” rating and a $6.00 price objective for the company. Finally, Noble Financial began coverage on Oncology Institute in a research report on Wednesday, July 23rd. They set an “outperform” rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Oncology Institute Stock Performance

Shares of TOI stock opened at $4.39 on Tuesday. The stock has a fifty day moving average of $3.57 and a 200 day moving average of $3.09. Oncology Institute has a 52 week low of $0.13 and a 52 week high of $4.50. The firm has a market capitalization of $410.47 million, a price-to-earnings ratio of -6.46 and a beta of 0.08. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 14.58.

Insider Buying and Selling at Oncology Institute

In other news, Director Growth I. L.P. M33 sold 6,018,168 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $3.09, for a total value of $18,596,139.12. Following the transaction, the director owned 7,932,389 shares in the company, valued at $24,511,082.01. This represents a 43.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers lifted its holdings in Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares in the last quarter. ProShare Advisors LLC purchased a new position in Oncology Institute in the 2nd quarter worth approximately $25,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Oncology Institute in the 2nd quarter worth approximately $32,000. State of Wyoming purchased a new position in Oncology Institute in the 2nd quarter worth approximately $37,000. Finally, XTX Topco Ltd lifted its holdings in Oncology Institute by 49.5% in the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company’s stock worth $63,000 after purchasing an additional 18,448 shares in the last quarter. 36.86% of the stock is currently owned by institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.